AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9637582 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood donation and willingness to be contacted by phone
Number of subjects: 0
Study 7727280 — intervention group
Group type: EXPERIMENTAL
Intervention: Cysteine 500 mg twice daily
Number of subjects: 16
Study 7727280 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 2690871 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 ppm nitrogen dioxide
Number of subjects: 60
Study 2690871 — intervention group
Group type: COMPARATOR
Intervention: Air (control)
Number of subjects: 60
Study 31507250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study 31507250 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy with integrated exposure and emotion-focused elements (CBT-EE)
Number of subjects: 0
Study 31507250 — intervention group
Group type: COMPARATOR
Intervention: Both CBT and CBT-EE
Number of subjects: 0
Study 30266529 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin drops (OFLX)
Number of subjects: 100
Study 30266529 — intervention group
Group type: EXPERIMENTAL
Intervention: Gelatin sponge patches
Number of subjects: 100
Study 30266529 — intervention group
Group type: COMPARATOR
Intervention: Spontaneous healing
Number of subjects: 100
Study 30266529 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic myringoplasty
Number of subjects: 100
Study 28277996 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric stimulation therapy (EST) used 4 times daily for 20 minutes per session.
Number of subjects: 23
Study 28277996 — intervention group
Group type: COMPARATOR
Intervention: Sham device (control group) used 4 times daily for 20 minutes per session.
Number of subjects: 23
Study 25460259 — intervention group
Group type: EXPERIMENTAL
Intervention: Fear reactivation using a virtual spider 10 min prior to VR exposure (reactivation group)
Number of subjects: 32
Study 25460259 — intervention group
Group type: COMPARATOR
Intervention: Control group exposed to a virtual plant 10 min prior to VR exposure
Number of subjects: 32
Study 23623506 — intervention group
Group type: EXPERIMENTAL
Intervention: FTCQ‐12 risk score (RS; Factor 2, Expectancy plus Factor 4, Purposefulness)
Number of subjects: 0
Study 23623506 — intervention group
Group type: EXPERIMENTAL
Intervention: MNWS craving
Number of subjects: 0
Study 21804463 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide (20 µg/day for 18 months)
Number of subjects: 2
Study 21804463 — intervention group
Group type: COMPARATOR
Intervention: Bisphosphonates (70 mg/week for 18 months)
Number of subjects: 2
Study 19333933 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab 5 mg/kg
Number of subjects: 40
Study 19333933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 16422446 — intervention group
Group type: EXPERIMENTAL
Intervention: Strobe light (4 Hz stroboscopic illumination)
Number of subjects: 32
Study 16422446 — intervention group
Group type: EXPERIMENTAL
Intervention: LCD shutter glasses (4 Hz stroboscopic illumination)
Number of subjects: 32
Study 16422446 — intervention group
Group type: COMPARATOR
Intervention: Normal room illumination (control condition)
Number of subjects: 32
Study 15297775 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic polyethylene glycol solution containing 50 microCi of [51Cr]EDTA administered through a nasoduodenal tube for intestinal lavage
Number of subjects: 52
Study 15297775 — intervention group
Group type: EXPERIMENTAL
Intervention: Double-blind, placebo-controlled food challenge (DBPCFC)
Number of subjects: 52
Study 15297775 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine and ECP concentrations
Number of subjects: 52
Study 15297775 — intervention group
Group type: EXPERIMENTAL
Intervention: Intestinal permeability assessment by 5-hour urinary excretion of [51Cr]EDTA
Number of subjects: 52
Study 15297775 — intervention group
Group type: EXPERIMENTAL
Intervention: Calprotectin analysis in native faecal samples
Number of subjects: 52
Study 11408434 — intervention group
Group type: EXPERIMENTAL
Intervention: High carbohydrate diet (75%)
Number of subjects: 12
Study 11408434 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra energy + high carbohydrate diet (CHO + E)
Number of subjects: 12
Study 11408434 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet (Hab)
Number of subjects: 12
Study 10771859 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm milk
Number of subjects: 52
Study 10771859 — intervention group
Group type: COMPARATOR
Intervention: Term milk
Number of subjects: 52
Study 1722511 — intervention group
Group type: EXPERIMENTAL
Intervention: Columbia 13-14 curet
Number of subjects: 90
Study 1722511 — intervention group
Group type: EXPERIMENTAL
Intervention: P-10 ultrasonic instrument
Number of subjects: 90
Study 1722511 — intervention group
Group type: EXPERIMENTAL
Intervention: Diamond-coated P-10 ultrasonic instrument
Number of subjects: 90
Study 1722511 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiformin/citric acid chemical treatment
Number of subjects: 90
Study 1722511 — intervention group
Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 90
Study 6181560 — intervention group
Group type: EXPERIMENTAL
Intervention: Transvesical prostatectomy
Number of subjects: 59
Study 6181560 — intervention group
Group type: COMPARATOR
Intervention: Transurethral prostatectomy
Number of subjects: 59
Study 6181560 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatectomy (in patients with upper urinary tract obstruction)
Number of subjects: 59
Study 6181560 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostatectomy (in patients with normal upper urinary tract)
Number of subjects: 59
Study 6181560 — intervention group
Group type: EXPERIMENTAL
Intervention: Total patient group
Number of subjects: 59
Study 6181560 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with renographic obstruction preoperatively
Number of subjects: 59
Study 6181560 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative patients with upper urinary tract obstruction
Number of subjects: 59
Study 6181560 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative patients with normal urography
Number of subjects: 59
Study 31475794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sacubitril-valsartan (target dose, 97 mg of sacubitril with 103 mg of valsartan twice daily)
Number of subjects: 4822
Study 31475794 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (target dose, 160 mg twice daily)
Number of subjects: 4822
Study 29137512 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronutrient powders distributed at microfinance meetings
Number of subjects: 0
Study 29137512 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 27680994 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus 1 of 4 complementary food supplements (CFSs) fed as a daily snack
Number of subjects: 5499
Study 27680994 — intervention group
Group type: COMPARATOR
Intervention: Control group (periodic child feeding counseling for mothers)
Number of subjects: 5499
Study 27680994 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling plus CFSs
Number of subjects: 5499
Study 24026156 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical microendoscopic discectomy and fusion (CMEDF)
Number of subjects: 70
Study 24026156 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 70
Study 20974542 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-based teaching session (90 minutes)
Number of subjects: 2
Study 20974542 — intervention group
Group type: COMPARATOR
Intervention: Conventional training (books, articles, web-based resources)
Number of subjects: 2
Study 19934822 — intervention group
Group type: EXPERIMENTAL
Intervention: ketorolac 0.4% 4 times a day
Number of subjects: 31
Study 19934822 — intervention group
Group type: EXPERIMENTAL
Intervention: bromfenac 0.09% 2 times a day
Number of subjects: 31
Study 19934822 — intervention group
Group type: EXPERIMENTAL
Intervention: nepafenac 0.1% 3 times a day
Number of subjects: 31
Study 19934822 — intervention group
Group type: COMPARATOR
Intervention: no NSAID
Number of subjects: 31
Study 17096178 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 percent glycerin trinitrate ointment and cryothermal anal dilators
Number of subjects: 48
Study 17096178 — intervention group
Group type: COMPARATOR
Intervention: 0.25 percent glycerin trinitrate ointment only
Number of subjects: 48
Study 17096178 — intervention group
Group type: COMPARATOR
Intervention: Cryothermal anal dilators only
Number of subjects: 48
Study 15011418 — intervention group
Group type: EXPERIMENTAL
Intervention: Olprinone hydrochloride (15 micrograms.kg‐1 bolus plus 0.1 microgram.kg‐1.min‐1 continuous administration)
Number of subjects: 56
Study 15011418 — intervention group
Group type: COMPARATOR
Intervention: Control group (no olprinone hydrochloride)
Number of subjects: 56
Study 11710410 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight Belt (WB)
Number of subjects: 14
Study 11710410 — intervention group
Group type: COMPARATOR
Intervention: No Weight Belt (NWB)
Number of subjects: 14
Study 9536857 — intervention group
Group type: EXPERIMENTAL
Intervention: Black tea (6 mugs per day)
Number of subjects: 65
Study 9536857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 7801664 — intervention group
Group type: EXPERIMENTAL
Intervention: Iomeprol 350 (IO)
Number of subjects: 49
Study 7801664 — intervention group
Group type: COMPARATOR
Intervention: Diatrizoate 370 (DIA)
Number of subjects: 49
Study 3197370 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II (1 pmol/min)
Number of subjects: 14
Study 31871055 — intervention group
Group type: EXPERIMENTAL
Intervention: Faecal volatile organic compounds (VOCs) associated with NEC
Number of subjects: 1326
Study 31871055 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual VOCs identified through discriminant analyses
Number of subjects: 1326
Study 31871055 — intervention group
Group type: COMPARATOR
Intervention: Faecal VOCs in NEC cases
Number of subjects: 1326
Study 29016943 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (Bev) added to radiotherapy/temozolomide
Number of subjects: 621
Study 29016943 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 621
Study 28302179 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloids (clinician's choice of lactated Ringer's solution or Plasma‐Lyte A®)
Number of subjects: 14000
Study 28302179 — intervention group
Group type: COMPARATOR
Intervention: Saline (0.9% sodium chloride)
Number of subjects: 14000
Study 28302179 — intervention group
Group type: EXPERIMENTAL
Intervention: Balanced crystalloids
Number of subjects: 14000
Study 26140401 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong opioids (oxycodone/morphine/meperidine)
Number of subjects: 1004
Study 26140401 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak opioids (codeine/propoxyphene/hydrocodone)
Number of subjects: 1004
Study 26140401 — intervention group
Group type: EXPERIMENTAL
Intervention: Opioid-naïve
Number of subjects: 1004
Study 24171779 — intervention group
Group type: EXPERIMENTAL
Intervention: Chungkookjang (35 g daily for 12 weeks)
Number of subjects: 120
Study 24171779 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 20484620 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral clonidine, 1.5 µg/kg every 4 hours starting the second week of life
Number of subjects: 36
Study 18332051 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of rifampicin
Number of subjects: 21711
Study 18332051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21711
Study 16997001 — intervention group
Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 28
Study 16997001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 14517773 — intervention group
Group type: EXPERIMENTAL
Intervention: Synthetic GLP-1 (7-36 amide) at 1.2 pmol/kg/min administered over a period of three hours during glucose injection.
Number of subjects: 8
Study 14517773 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered during the fasting state.
Number of subjects: 8
Study 14517773 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administered until 120 or 30 min before the glucose load.
Number of subjects: 8
Study 14517773 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administered until -30 min before glucose load.
Number of subjects: 8
Study 14517773 — intervention group
Group type: EXPERIMENTAL
Intervention: GLP-1 administration during glucose injection.
Number of subjects: 8
Study 10929918 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin 1,700 mg/d
Number of subjects: 31
Study 10929918 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 8938531 — intervention group
Group type: EXPERIMENTAL
Intervention: alpha-interferon treatment
Number of subjects: 100
Study 8421087 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine (10 mg, twice daily for 7 days)
Number of subjects: 15
Study 8421087 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 3570479 — intervention group
Group type: EXPERIMENTAL
Intervention: Fusidic acid 1% eye preparation, given four to six times daily for one week
Number of subjects: 248
Study 3570479 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol 0.5% eye drops, given four to six times daily for one week
Number of subjects: 248
Study 29226818 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored pacemaker rate‐response programming based on the force-frequency relationship (FFR)
Number of subjects: 90
Study 29226818 — intervention group
Group type: COMPARATOR
Intervention: Conventional rate‐response programming
Number of subjects: 90
Study 27402466 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser (L)
Number of subjects: 56
Study 27402466 — intervention group
Group type: EXPERIMENTAL
Intervention: Laser with topical antifungal therapy (L + T)
Number of subjects: 56
Study 27402466 — intervention group
Group type: COMPARATOR
Intervention: Topical antifungal treatment (T)
Number of subjects: 56
Study 25276082 — intervention group
Group type: EXPERIMENTAL
Intervention: bimatoprost (0.03%)
Number of subjects: 140
Study 25276082 — intervention group
Group type: EXPERIMENTAL
Intervention: latanoprost (0.005%)
Number of subjects: 140
Study 25276082 — intervention group
Group type: EXPERIMENTAL
Intervention: travoprost (0.004%)
Number of subjects: 140
Study 25276082 — intervention group
Group type: COMPARATOR
Intervention: timolol (0.5%)
Number of subjects: 140
Study 23957382 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous CSF drainage with intermittent ICP monitoring (open‐EVD group)
Number of subjects: 60
Study 23957382 — intervention group
Group type: COMPARATOR
Intervention: Continuous ICP monitoring with intermittent CSF drainage (monitor‐ICP group)
Number of subjects: 60
Study 21357642 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Disease Self‐Management Program (CDSMP)
Number of subjects: 0
Study 21357642 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control
Number of subjects: 0
Study 18755458 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral therapy
Number of subjects: 198
Study 18755458 — intervention group
Group type: COMPARATOR
Intervention: No therapy (Control)
Number of subjects: 198
Study 17161051 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF) at 5 to 10 microg/kg per day subcutaneously for 5 days
Number of subjects: 18
Study 17161051 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 17161051 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF) at 5 microg/kg per day
Number of subjects: 18
Study 17161051 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocyte colony stimulating factor (G-CSF) at 10 microg/kg per day
Number of subjects: 18
Study 14576541 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-Classic
Number of subjects: 200
Study 14576541 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft Seal LM
Number of subjects: 200
Study 10933738 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture repair
Number of subjects: 200
Study 10933738 — intervention group
Group type: COMPARATOR
Intervention: Mesh repair
Number of subjects: 200
Study 8718436 — intervention group
Group type: EXPERIMENTAL
Intervention: Troglitazone (400 mg/day p.o.)
Number of subjects: 284
Study 8718436 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study 1524753 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified Kapur scale
Number of subjects: 0
Study 1524753 — intervention group
Group type: COMPARATOR
Intervention: Standard Kapur scale
Number of subjects: 0
Study 1524753 — intervention group
Group type: COMPARATOR
Intervention: Two denture adhesives
Number of subjects: 0
Study 6202090 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacriosol
Number of subjects: 30
Study 6202090 — intervention group
Group type: EXPERIMENTAL
Intervention: Isopto Plain
Number of subjects: 30
Study 6202090 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 30
Study 31121394 — intervention group
Group type: EXPERIMENTAL
Intervention: Silexan (80 mg/day)
Number of subjects: 212
Study 31121394 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212
Study 29189308 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactotripeptides (4.5 mg/d, thrice on exercise day and day after)
Number of subjects: 22
Study 29189308 — intervention group
Group type: COMPARATOR
Intervention: Placebo (4.5 mg/d, thrice on exercise day and day after)
Number of subjects: 22
Study 27050069 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetes-specific oral nutritional supplement (ONS)
Number of subjects: 40
Study 27050069 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric standard ONS (control)
Number of subjects: 40
Study 24314909 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharyngeal electrical stimulation (PES)
Number of subjects: 18
Study 24314909 — intervention group
Group type: EXPERIMENTAL
Intervention: Paired associative stimulation (PAS)
Number of subjects: 18
Study 24314909 — intervention group
Group type: EXPERIMENTAL
Intervention: Repetitive TMS (rTMS)
Number of subjects: 18
Study 24314909 — intervention group
Group type: COMPARATOR
Intervention: Sham interventions
Number of subjects: 18
Study 23979567 — intervention group
Group type: EXPERIMENTAL
Intervention: Optical frequency domain imaging (OFDI)
Number of subjects: 97
Study 23979567 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention on identified FS)
Number of subjects: 97
Study 20795384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pneumo 23 and Act-HIB vaccines
Number of subjects: 256
Study 18463424 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical Visthesia drops
Number of subjects: 18
Study 18463424 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Healon)
Number of subjects: 18
Study 15962453 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) daily
Number of subjects: 700
Study 15962453 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human growth hormone (rhGH) alternate days
Number of subjects: 700
Study 15962453 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study 12756509 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenofibrate
Number of subjects: 54
Study 12756509 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Number of subjects: 54
Study 12756509 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 54
Study 12756509 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypolipidemic diet
Number of subjects: 54
Study 12756509 — intervention group
Group type: COMPARATOR
Intervention: Control (normolipidemic participants)
Number of subjects: 54
Study 12756509 — intervention group
Group type: COMPARATOR
Intervention: Control (healthy subjects)
Number of subjects: 54
Study 10048647 — intervention group
Group type: EXPERIMENTAL
Intervention: Microultrasonic inserts (Slimline FSI left and right‐Dentsply)
Number of subjects: 30
Study 10048647 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional ultrasonic insert (P10 insert‐Dentsply)
Number of subjects: 30
Study 8622103 — intervention group
Group type: EXPERIMENTAL
Intervention: isepamicin (15 mg/kg once daily)
Number of subjects: 267
Study 8622103 — intervention group
Group type: COMPARATOR
Intervention: amikacin (7.5 mg/kg twice daily)
Number of subjects: 267
Study 2265155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.5% with epinephrine
Number of subjects: 46
Study 2265155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% with epinephrine
Number of subjects: 46
Study 2265155 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 1.0% with epinephrine
Number of subjects: 46
Study 728895 — intervention group
Group type: EXPERIMENTAL
Intervention: Levamisole (doses ranged from 65 to 410 mg/m2, maximum tolerated dose 358 mg/m2)
Number of subjects: 0
Study 728895 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 0
Study 31309239 — intervention group
Group type: EXPERIMENTAL
Intervention: Teriparatide + WBV
Number of subjects: 35
Study 31309239 — intervention group
Group type: COMPARATOR
Intervention: Teriparatide
Number of subjects: 35
Study 29055242 — intervention group
Group type: EXPERIMENTAL
Intervention: Task‐oriented Functional Training (TFT)
Number of subjects: 43
Study 29055242 — intervention group
Group type: EXPERIMENTAL
Intervention: Wii training
Number of subjects: 43
Study 26241598 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention (n=242)
Number of subjects: 600
Study 26241598 — intervention group
Group type: COMPARATOR
Intervention: Assessed control (n=237)
Number of subjects: 600
Study 26241598 — intervention group
Group type: COMPARATOR
Intervention: No-contact control (n=121)
Number of subjects: 600
Study 23895296 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduced toxicant prototype (RTP) cigarette (7 mg ISO tar yield)
Number of subjects: 0
Study 23895296 — intervention group
Group type: COMPARATOR
Intervention: Commercial cigarettes
Number of subjects: 0
Study 21320198 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A (anti-hypertensive education)
Number of subjects: 120
Study 21320198 — intervention group
Group type: EXPERIMENTAL
Intervention: Group B (anti-hypertensive education + healthy lifestyle education)
Number of subjects: 120